SA PRO
Free Account
ResMed Inc.RMDNYSE
LOADING
|||
OverviewNewsFundamentalsEarningsAnalysts

Earnings & Revenue Estimates

2026E$10.93(13 analysts)
P/E26x
Current: 26.3x
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+7.35%
EPS+10.71%
FY2028
Rev+6.79%
EPS+9.01%
FY2029
Rev+7.38%
EPS+6.42%

Earnings Surprises

Recent Analyst Actions

Dec 18, 2025Stifel Nicolaus
ResMed (RMD) PT Lowered to $260 at Stifel
Target:$260.00
+5.7%from $245.94
Dec 16, 2025Robert W. Baird
ResMed downgraded to Neutral from Outperform at Baird
Target:$275.00
+8.7%from $253.07
Dec 12, 2025UBS
ResMed (RMD) PT Raised to $345 at UBS
Target:$345.00
+37.2%from $251.38
Nov 3, 2025Robert W. Baird
ResMed price target lowered to $300 from $320 at Baird
Target:$300.00
+21.5%from $246.88
Oct 31, 2025KeyBanc
ResMed price target raised to $299 from $298 at KeyBanc
Target:$299.00
+22.5%from $244.12
Oct 31, 2025Morgan Stanley
ResMed price target raised to $305 from $304 at Morgan Stanley
Target:$305.00
+20.9%from $252.26
Oct 21, 2025Morgan Stanley
ResMed price target raised to $304 from $298 at Morgan Stanley
Target:$304.00
+12.0%from $271.41
Oct 13, 2025Wells Fargo
ResMed initiated with an Equal Weight at Wells Fargo
Target:$280.00
+2.9%from $272.00
May 20, 2025Morgan Stanley
Morgan Stanley sees 'modest' earnings impact to ResMed from Apnimed
Target:$286.00
+15.3%from $248.14
Apr 24, 2025KeyBanc
ResMed price target raised to $274 from $269 at KeyBanc
Target:$274.00
+17.8%from $232.65
Apr 16, 2025Mizuho Securities
ResMed price target lowered to $265 from $280 at Mizuho
Target:$265.00
+25.3%from $211.49
Mar 5, 2025Stifel Nicolaus
ResMed price target lowered to $240 from $250 at Stifel
Target:$240.00
+7.2%from $223.83
Jan 31, 2025Piper Sandler
ResMed price target raised to $260 from $252 at Piper Sandler
Target:$260.00
+10.1%from $236.18
Dec 12, 2024Stifel Nicolaus
ResMed initiated with a Hold at Stifel
Target:$250.00
+3.1%from $242.51
Oct 1, 2024RBC Capital
ResMed (RMD) PT Raised to $224 at RBC Capital
Target:$224.00
-6.3%from $238.95
Sep 23, 2024Robert W. Baird
Baird Starts ResMed (RMD) at Outperform
Target:$280.00
+13.7%from $246.18
Sep 18, 2024Wolfe Research
Wolfe Research Downgrades ResMed (RMD) to Underperform
Target:$180.00
-28.3%from $250.88
Apr 10, 2024RBC Capital
ResMed (RMD) PT Raised to $187 at RBC Capital
Target:$187.00
-3.7%from $194.27
Apr 1, 2024Stifel Nicolaus
ResMed (RMD) PT Raised to $224 at Stifel
Target:$224.00
+13.1%from $198.03
Oct 27, 2023Oppenheimer
How Sleep Device Player ResMed Is Gaining Philips' Market Share In Flow Generator Market - Analysts Weigh In
Target:$175.00
+30.0%from $134.65
Sep 6, 2023Needham
Needham & Company Upgrades ResMed (RMD) to Buy
Target:$180.00
+17.0%from $153.89
Jun 20, 2022RBC Capital
ResMed (RMD) Stock: $244 Target And Outperform Rating
Target:$244.00
+23.5%from $197.57
Apr 29, 2022RBC Capital
RBC Capital Maintains Sector Perform on ResMed, Lowers Price Target to $233
Target:$233.00
+16.0%from $200.81
Oct 14, 2021Oppenheimer
Oppenheimer Sees Apnimeds Ph2 Results Worth Watching for ResMed (RMD)
Target:$312.00
+22.9%from $253.77
Aug 4, 2021Morgan Stanley
ResMed (RMD) PT Raised to $250 at Morgan Stanley
Target:$250.00
-8.0%from $271.87

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance